stars 1 stars 2 stars 3

Angiochem is a clinical-stage biotechnology company discovering and developing novel drugs that are crossing the blood-brain barrier to treat brain diseases. These new Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention. Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the treatment of a wide range of brain diseases including brain cancers, lysosomal storage disorders, pain and others. The EPiC platform has been strongly validated in humans.

Angiochem Questions

The Angiochem annual revenue was $5.6 million in 2026.

John Huss is the CEO of Angiochem.

3 people are employed at Angiochem.

Angiochem is based in Westmount, Quebec.

The NAICS codes for Angiochem are [3254, 541, 32, 54, 32541, 325].

The SIC codes for Angiochem are [87, 28, 873, 283].

Top Angiochem Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users